Comparison the effect of valerian and gabapentin on RLS and sleep quality in hemodialysis patients: A randomized clinical trial
Iman Hajizadeh
Critical Care Nursing Student, Student Research Committee, School of Nursing and Midwifery, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Search for more papers by this authorMahdieh Jamshidi
Department of Internal Medicine, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Search for more papers by this authorMajid Kazemi
Department of Medical-Surgical Nursing, School of Nursing and Midwifery; Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Search for more papers by this authorHossein Kargar
Department of Traditional Medicine, School of Persian Medicine, Kerman University of Medical Sciences, Kerman, Iran
Search for more papers by this authorCorresponding Author
Tabandeh Sadeghi
Department of Pediatric Nursing, School of Nursing and Midwifery; Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Correspondence
Tabandeh Sadeghi, Department of Pediatric Nursing, School of Nursing and Midwifery, Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Parastar Street, Rafsanjan 7718796755, Iran.
Email: [email protected]; [email protected]
Search for more papers by this authorIman Hajizadeh
Critical Care Nursing Student, Student Research Committee, School of Nursing and Midwifery, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Search for more papers by this authorMahdieh Jamshidi
Department of Internal Medicine, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Search for more papers by this authorMajid Kazemi
Department of Medical-Surgical Nursing, School of Nursing and Midwifery; Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Search for more papers by this authorHossein Kargar
Department of Traditional Medicine, School of Persian Medicine, Kerman University of Medical Sciences, Kerman, Iran
Search for more papers by this authorCorresponding Author
Tabandeh Sadeghi
Department of Pediatric Nursing, School of Nursing and Midwifery; Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
Correspondence
Tabandeh Sadeghi, Department of Pediatric Nursing, School of Nursing and Midwifery, Non-Communicable Diseases Research Center, Rafsanjan University of Medical Sciences, Parastar Street, Rafsanjan 7718796755, Iran.
Email: [email protected]; [email protected]
Search for more papers by this authorAbstract
Introduction
This study aimed to compare the effect of valerian and gabapentin on restless legs syndrome (RLS) and sleep quality in HD patients.
Methods
In this cross over clinical trial study, 40 HD patients allocated into a valerian and gabapentin group. In the first phase of the study, Group A received valerian and Group B received gabapentin 1 h before bedtime for 1 month. In the second phase, the two groups' treatment regimen was swapped. After a 1-month washout period, the same process was repeated on the crossover groups.
Results
After the first phase, the mean score of RLS was lower in the gabapentin group. But there was no statistically significant difference between the two groups in terms of sleep quality score before and after the first and second interventions.
Conclusion
Gabapentin is more effective than valerian in improving RLS, but both are equally effective in improving sleep quality.
CONFLICT OF INTEREST STATEMENT
The authors declare no conflicts of interest.
REFERENCES
- 1Gholami M, Asgari P, Nasrabadi SSH, Sadat Z, Saberi F. The relationship between attitude and practical commitment to prayer and death anxiety in patients with chronic renal failure. Iran J Psychiatr Nurs. 2020; 7(6): 18–25.
- 2Azari S, Kiani G, Hejazi M. The effect of acceptance and commitment based group therapy on increasing the quality of life in kidney transplant and hemodialysis patients in Zanjan city: a randomized clinical trial study. J Rafsanjan Univ Med Sci. 2020; 19(6): 555–68.
- 3Bayati L, Kazemi M, Sadeghi T. Comparison of the effect of education by peer and nurse on self-care in hemodialysis patients. Hayat J. 2019; 25(3): 277–88.
- 4Baghcheghi N. Comparison of depression and quality of life between patients on hemodialysis and their spouses. Avicenna J Nurs Midwifery Care. 2020; 28(2): 136–43.
10.30699/ajnmc.28.2.136 Google Scholar
- 5Taherkhani M, Mohammadi F, Rashvand F, Motalebi SA. Predictors of perceived caregiving burden among caregivers of elderly dialysis patients. Iran J Ageing. 2022; 16(4): 482–97.
- 6Ramezani T, Gh S, Gharlipour Z, Sh P, Mohebi S. The effect of educational program on physical activity and sleep in hemodialysis patients: applying the self-efficacy theory. J Health. 2019; 10(2): 156–68.
10.29252/j.health.10.2.156 Google Scholar
- 7Schormair B, Zhao C, Bell S, Tilch E, Salminen AV, Pütz B, et al. Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. Lancet Neurol. 2017; 16(11): 898–907.
- 8Wijemanne S, Ondo W. Restless legs syndrome: clinical features, diagnosis and a practical approach to management. Pract Neurol. 2017; 17(6): 444–52.
- 9Kwatra V, Khan MA, Quadri SA, Cook TS. Differential diagnosis and treatment of restless legs syndrome: a literature review. Cureus. 2018; 10(9): 3297–308.
- 10Habibzadeh H, Lazari N, Ghanei GR. Relationship between restless legs syndrome and sleep quality in hemodialysis patients. Medsurg Nurs. 2013; 2(1-2): 57–62.
- 11Hajian S, Nikfam MRR, Esmayeilzad Z. Comparison of the effects of pramipexole and gabapentin on the treatment of restless leg syndrome in end-stage chronic renal failure patients undergoing hemodialysis. J Nephropathol. 2020; 9(3):e25.
10.34172/jnp.2020.25 Google Scholar
- 12Lin X-W, Zhang J-F, Qiu M-Y, Ni L-Y, Yu H-L, Kuo S-H, et al. Restless legs syndrome in end stage renal disease patients undergoing hemodialysis. BMC Neurol. 2019; 19(1): 1–7.
- 13Hoseini Amiri M, Bidaki R, Avazbakhsh MH, Mirhoseini H, Yamola M. Prevalence and correlates of restless legs syndrome in chronic renal failure patients undergoing hemodialysis. Koomesh. 2019; 21(3): 493–7.
- 14Bastani M, Ghasemi G. The effect of selected core stability exercises on restless legs syndrome and quality of life in the elderly undergoing hemodialysis. Qom Univ Med Sci J. 2018; 12(8): 48–58.
10.29252/qums.12.8.48 Google Scholar
- 15Fröhlich AC, Eckeli AL, Bacelar A, Poyares D, Pachito DV, Stelzer FG, et al. Brazilian consensus on guidelines for diagnosis and treatment for restless legs syndrome. Arq Neuropsiquiatr. 2015; 73: 260–80.
- 16Ali M, Iram H, Nasim F, Solangi SA, Junejo AM, Nisa NU, et al. Comparison of the efficacy of gabapentin versus levodopa-C for the treatment of restless legs syndrome in end-stage renal disease on hemodialysis patients. Cureus. 2020; 12(12): 12034–39.
- 17Shinjyo N, Waddell G, Green J. Valerian root in treating sleep problems and associated disorders—a systematic review and meta-analysis. J Evid Based Integr Med. 2020; 25:2515690X20967323.
- 18Hashemi H, Kheirkhah D, Aghajani M. The effect of massage with glycerin oil on restless leg syndrome in hemodialysis patients. J complement med. 2016; 6(19): 1500–10.
- 19Siegfried E, Glenn E. Use of olive oil for the treatment of seborrheic dermatitis in children. Arch Pediatr Adolesc Med. 2012; 166(10): 967.
- 20Pineau S, Legros C, Mattei C. The medical use of lemon balm (Melissa officinalis) and valerian (Valeriana officinalis) as natural sedatives: insight into their interactions with GABA transmission. Int J Clin Pharmacol Pharmacother. 2016; 1(112): 2.
- 21Salehi S, Valiee S, Roshani D, Fathi M. Effect of valerian capsule on anxiety and quality of life in type 1 diabetes: a clinical trial. Sci J Kurdistan Univ Med Sci. 2019; 24(3): 55–66.
- 22Tammadon MR, Nobahar M, Hydarinia-Naieni Z, Ebrahimian A, Ghorbani R, Vafaei AA. The effects of valerian on sleep quality, depression, and state anxiety in hemodialysis patients: a randomized, double-blind, crossover clinical trial. Oman Med J. 2021; 36(2):e255.
- 23Samaei A, Nobahar M, Hydarinia-Naieni Z, Ebrahimian AA, Tammadon MR, Ghorbani R, et al. Effect of valerian on cognitive disorders and electroencephalography in hemodialysis patients: a randomized, cross over, double-blind clinical trial. BMC Nephrol. 2018; 19(1): 1–10.
- 24Malekshahi F, Aryamanesh F, Fallahi S. The effects of massage therapy on sleep quality of patients with end-stage renal disease undergoing hemodialysis. Sleep Hypn. 2018; 20: 91–5.
- 25Garcia-Borreguero D, Cano-Pumarega I, Malo CG, Velarde JAC, Granizo JJ, Wanner V. Reduced response to gabapentin enacarbil in restless legs syndrome following long-term dopaminergic treatment. Sleep Med. 2019; 55: 74–80.
- 26Hassanzadeh M, Sajadi SA, Farsi Z. Comparison effect of Sedamin capsule and inhaling lavender essence on sleep quality of hospitalized patients in cardiac care unit. Mil Caring Sci J. 2018; 4(3): 187–97.
- 27Lo H-S, Yang C-M, Lo HG, Lee C-Y, Ting H, Tzang B-S. Treatment effects of gabapentin for primary insomnia. Clin Neuropharmacol. 2010; 33(2): 84–90.
- 28Razazian N, Azimi H, Heidarnejadian J, Afshari D, Ghadami MR. Gabapentin versus levodopa-c for the treatment of restless legs syndrome in hemodialysis patients: a randomized clinical trial. Saudi J Kidney Dis Transpl. 2015; 26(2): 271–8.
- 29Inoue Y, Hirata K, Hoshino Y, Yamaguchi Y. Difference in background factors between responders to gabapentin enacarbil treatment and responders to placebo: pooled analyses of two randomized, double-blind, placebo-controlled studies in Japanese patients with restless legs syndrome. Sleep Med. 2021; 85: 138–46.
- 30Jamilian M, Jamilian HR. Assessing the effect of gabapentin on improving quality of life and sleep disruption in postmenopausal women. J Arak Univ Med Sci. 2015; 18(1): 16–23.
- 31Barton DL, Atherton PJ, Bauer BA, Moore DF Jr, Mattar BI, LaVasseur BI, et al. The use of Valeriana officinalis (valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study: NCCTG trial, N01C5. J Support Oncol. 2011; 9(1): 24–31.
